Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (DEFICIT)

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
Total
Series B Warrant
Common Stock Options
Common Stock Warrants
Prefunded Warrants
Common Stock
Common Stock
Series B Warrant
Common Stock
Common Stock Options
Common Stock
Common Stock Warrants
Common Stock
Prefunded Warrants
Additional Paid-In Capital
Additional Paid-In Capital
Series B Warrant
Additional Paid-In Capital
Common Stock Options
Additional Paid-In Capital
Common Stock Warrants
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2019           182,895,247                  
Beginning balance at Dec. 31, 2019 $ 548,058         $ 182,895         $ 32,538,445       $ (32,173,282)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense 64,142                   64,142        
Warrant exercise (in shares)             312,500                
Warrant exercise   $ 26,563         $ 313         $ 26,250      
Net loss (2,341,660)                           (2,341,660)
Ending balance (in shares) at Mar. 31, 2020           183,207,747                  
Ending balance at Mar. 31, 2020 (1,702,897)         $ 183,208         32,628,837       (34,514,942)
Beginning balance (in shares) at Dec. 31, 2019           182,895,247                  
Beginning balance at Dec. 31, 2019 548,058         $ 182,895         32,538,445       (32,173,282)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Net loss (5,058,592)                            
Ending balance (in shares) at Sep. 30, 2020           250,074,415                  
Ending balance at Sep. 30, 2020 1,853,367         $ 250,074         38,835,167       (37,231,874)
Beginning balance (in shares) at Mar. 31, 2020           183,207,747                  
Beginning balance at Mar. 31, 2020 (1,702,897)         $ 183,208         32,628,837       (34,514,942)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense 28,709                   28,709        
Net loss (1,420,236)                           (1,420,236)
Ending balance (in shares) at Jun. 30, 2020           183,207,747                  
Ending balance at Jun. 30, 2020 (3,094,424)         $ 183,208         32,657,546       (35,935,178)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense 148,365                   148,365        
Common stock and warrants issued (in shares)           56,333,334                  
Common stock and warrants issued 6,085,589         $ 56,333         6,029,256        
Warrant exercise (in shares)                   10,533,334          
Warrant exercise         $ 10,533         $ 10,533          
Net loss (1,296,696)                           (1,296,696)
Ending balance (in shares) at Sep. 30, 2020           250,074,415                  
Ending balance at Sep. 30, 2020 1,853,367         $ 250,074         38,835,167       (37,231,874)
Beginning balance (in shares) at Dec. 31, 2020           288,074,415                  
Beginning balance at Dec. 31, 2020 450,786         $ 288,074         38,896,693       (38,733,981)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense (in shares)           600,000                  
Stock-based compensation expense 146,580         $ 600         145,980        
Warrant exercise (in shares)                 67,166,667 11,800,000          
Warrant exercise       $ 4,030,000 $ 11,800       $ 67,167 $ 11,800       $ 3,962,833  
Net loss (2,160,517)                           (2,160,517)
Ending balance (in shares) at Mar. 31, 2021           367,641,082                  
Ending balance at Mar. 31, 2021 2,478,649         $ 367,641         43,005,506       (40,894,498)
Beginning balance (in shares) at Dec. 31, 2020           288,074,415                  
Beginning balance at Dec. 31, 2020 450,786         $ 288,074         38,896,693       (38,733,981)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Warrant exercise (in shares)         11,800,000                    
Net loss (6,009,362)                            
Ending balance (in shares) at Sep. 30, 2021           476,108,445                  
Ending balance at Sep. 30, 2021 8,264,782         $ 476,108         52,532,017       (44,743,343)
Beginning balance (in shares) at Mar. 31, 2021           367,641,082                  
Beginning balance at Mar. 31, 2021 2,478,649         $ 367,641         43,005,506       (40,894,498)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense 111,699                   111,699        
Warrant exercise (in shares)               106,250 28,333,334            
Warrant exercise     $ 4,783 1,700,000       $ 107 $ 28,333       $ 4,676 1,671,667  
Net loss (2,024,027)                           (2,024,027)
Ending balance (in shares) at Jun. 30, 2021           396,080,666                  
Ending balance at Jun. 30, 2021 2,271,104         $ 396,081         44,793,548       (42,918,525)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense (in shares)           750,000                  
Stock-based compensation expense 485,723         $ 750         484,973        
Common stock and warrants issued (in shares)           58,111,112                  
Common stock and warrants issued 6,062,774         $ 58,111         6,004,663        
Warrant exercise (in shares)                 21,166,667            
Warrant exercise       $ 1,269,999         $ 21,166         $ 1,248,833  
Net loss (1,824,818)                           (1,824,818)
Ending balance (in shares) at Sep. 30, 2021           476,108,445                  
Ending balance at Sep. 30, 2021 $ 8,264,782         $ 476,108         $ 52,532,017       $ (44,743,343)